Germany Defies Pharma Backlash, Hikes Drug Rebate to 15.5%

Germany’s lawmakers had no shortage of warnings. Drugmakers objected. Trade groups objected. So did opposition voices inside the country’s own government. The reform passed anyway.

Late on Friday, the Bundestag, Germany’s lower house of parliament, approved a health insurance financial reform package by 318 votes to 284, with four abstentions. That is not a comfortable margin. The Bundesrat, the upper house, then gave its blessing, formally clearing the way for the measures to take effect.

The change that matters most is a single number that more than doubled. The fixed markdown drugmakers must pay on the list prices of their branded products climbs from 7% to 15.5%, according to a Bundestag announcement on 10 July. Everything else in the package—higher co-pays on prescription drugs, tighter insurance rules for married couples, and more centers on that central squeeze, as Deutsche Welle reported.

The arithmetic behind it is straightforward. Germany wants to pull roughly €16.3 billion ($18.6 billion) in costs out of its statutory health insurance system next year, with the potential to stretch that to more than €38.1 billion ($43.5 billion) by 2030. Someone has to fund that gap, and a meaningful share of it now lands on the industry.

The pushback wasn’t entirely wasted, though. A variable rebate proposal — which the Bundestag described as intended to generate steady additional revenue over the long run — was stripped out of the plan after industry opposition earlier this summer. Germany had already signalled the retreat in mid-June, when Reuters reported it was dropping the variable discount structure in favour of the fixed rebate that ultimately made it into Friday’s measure. It’s a real win, if a narrow one.

Why any of this registers beyond Germany’s borders comes down to the country’s role in the European market. Germany’s quick reimbursement turnaround means novel medicines can launch there earlier than almost anywhere else in the bloc. That makes it a proving ground, and it means pricing decisions taken in Berlin ripple outward in a way that decisions in smaller markets don’t.

The industry’s response was blunt. VFA, the country’s leading trade group for research-based drugmakers, came out swinging after the vote, warning that the reforms would weigh heavily on both the research-based pharmaceutical sector and the medical care available to people in Germany. Its sharper complaint was about the process itself: the group argues that as the bill moved through parliament, the burdens on pharmaceutical companies weren’t eased but deepened, and that while other players in the system won some relief, the industry’s load grew in several areas.

VFA also put a figure on it. By the group’s estimate, the 15.5% fixed manufacturer discount will push the industry’s burden from an originally anticipated €1.1 billion to somewhere near €3.2 billion in 2027 alone, close to a tripling. The trade group raised objections to price-quantity regulation and to steeper discounts on vaccines as well.

Some companies stopped waiting for the vote to make their views known. Earlier this year, Eli Lilly and German mainstay Boehringer Ingelheim both said they were scaling back separate planned investments in Germany, citing the drug discount measures wrapped into the reform effort. That’s a notable pair, one of the largest US drugmakers and one of Germany’s own. Leadership at Novartis and Pfizer piled on with criticism of their own.

All of this is unfolding against a noisier backdrop. US trade policy, the Trump administration’s tariff threats, plus the White House’s “most favored nation” drug pricing framework have dragged the pricing policies of other wealthy countries into the spotlight, and Germany’s reforms landed squarely in it. Novartis chief Vas Narasimhan captured the industry’s framing back in late April, arguing that policies like this send the wrong signal to a high-innovation industry like ours at a moment when the US and China are pouring money into their biotech ecosystems.